Published August 24, 2022
Hospitalization risk among nonvalvular atrial fibrillation (NVAF) and COVID-19 patients undergoing apixaban treatment
A study to evaluate the risk of hospitalization among nonvalvular atrial fibrillation (NVAF) patients with an outpatient COVID-19 diagnosis who discontinued compared to those who continued apixaban treatment, has been published in the journal Current Medical Research and Opinion.
Steven Deitelzweig, MD, System Department Chair of Hospital Medicine, Ochsner Health and Professor of Medicine, The University of Queensland, Ochsner Clinical School, authored the study utilizing data identified from over 7800 apixaban patients with COVID-19 in the Optum Clinformatics claims database (01APR2020-31MAR2021).
Patients were followed from COVID-19 diagnosis to a change of continuation or discontinuation status, switch, death, end of continuous coverage, or study end, whichever occurred first.
The study concluded NVAF patients with COVID-19 who discontinued apixaban had a higher risk of hospitalization and thrombotic events vs. those who continued apixaban, with no significant difference in bleeding-related hospitalization.
